MA-RENAGADE-THERAPEUTICS
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines to correct disease, today announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures.
ReNAgade has built a comprehensive and complementary platform that combines its proprietary delivery technologies, including novel lipid nanoparticles (LNPs), with a broad array of coding, editing, and gene insertion tools, in an all-RNA system. ReNAgade aims to address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body, substantially expanding the potential addressable disease market. The Company has an established Joint Venture with Orna Therapeutics Inc., combining ReNAgade’s delivery platform with Orna’s circular RNA technology. Subsequently, Orna has entered into a collaboration with Merck, which includes technologies developed under the Orna/ReNAgade JV.
“ReNAgade was founded on a bold idea – to dramatically transcend the boundaries of RNA medicine, a field that has made great strides but remains in its infancy,” said Ansbert Gadicke, M.D., Managing Partner of MPM Bioimpact and Founder of ReNAgade. “By innovating on delivery technology and bringing an array of genomic medicine tools under one roof, ReNAgade is poised to deliver RNA to organs and tissues not previously accessible. ReNAgade’s joint venture with Orna provides early validation of the technologies that ReNAgade will continue to bring forward.”
Founded by MPM BioImpact, ReNAgade is led by Chairman and Chief Executive Officer Amit D. Munshi, an industry veteran with more than 30 years of experience leading biotech companies and most recently the CEO of Arena Pharmaceuticals, with support from a world-class executive and scientific team with deep, translational expertise across multiple RNA modalities. Pete Smith, Ph.D., Chief Scientific Officer and an Executive Partner at MPM BioImpact, joins from Alnylam having previously served as Chief Early Development Officer and prior to that Senior Vice President and Head of R&D Nonclinical at Moderna, while Ciaran Lawlor, Ph.D., joins as Chief Operating Officer from Boston Consulting Group, having previously held multiple scientific roles at Moderna. Brian Shuster joins as Chief Business Officer from Bristol Myers Squibb. Brian previously worked at Johnson & Johnson where he led acquisitions, divestitures and equity investing, and at J.P. Morgan, where he worked with biotech companies on strategic and financing transactions.
“In order to fulfill our mission to develop RNA medicines with the potential to treat any disease anywhere in the body, we have curated a world-class, multidisciplinary team who have collectively achieved 25 NDAs, including four in RNA medicines, and 200 INDs, and have been pioneers in the field of RNA medicines,” said Amit D. Munshi, Chief Executive Officer of ReNAgade. “We are further buoyed by the support of our long-term investors and validated by the progress we have made to date – making us well-positioned to expand the reach of RNA medicine far beyond what was previously thought possible.”
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics – RNA Without Limits
For more information about the company, its technologies, and its leadership, visit https://www.renagadetx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005422/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Board Unveils New Foresight and Signals Products: Revolutionizing Business Planning with AI and Economic Intelligence19.2.2025 15:00:00 CET | Press release
Board, the leading Enterprise Planning Platform, is transforming the way businesses anticipate and adapt to economic shifts with today’s announcement of Board Foresight and Board Signals. These cutting-edge solutions, developed as a result of Board’s recent acquisition of Prevedere, empower enterprises with real-time economic indicators, predictive analytics, and the expertise of Board’s in-house economists—all backed by exclusive access to over 5 million global datasets. This release marks a huge step forward in completing Board’s product vision. By harnessing the power of macroeconomic intelligence, the Board Enterprise Planning Platform now enables more comprehensive, collaborative, and continuous planning capabilities than ever before. Board Foresight and Signals give business leaders the ability to look beyond internal historical data, forecast with greater accuracy, scenario plan with more agility, and make strategic decisions with confidence in an increasingly volatile world. Bo
PPG, PPG Foundation invested $18.4 million in communities worldwide in 202419.2.2025 15:00:00 CET | Press release
PPG (NYSE:PPG) and the PPG Foundation today announced that they invested $18.4 million worldwide in 2024, an increase of $900,000 over 2023. The 2024 funding supported more than 400 community partners and programs that focus on advancing education and delivering community sustainability while encouraging PPG employee volunteerism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219834296/en/ PPG and the PPG Foundation invested $18.4 million worldwide in 2024 to programs that focus on advancing education and delivering community sustainability while encouraging PPG employee volunteerism. (Photo: Business Wire) “Around the world, PPG’s 2024 community engagement investments aimed to inspire students and aspiring STEM leaders, beautify neighborhoods and give our employees meaningful ways to give back,” said Malesia Dunn, executive director, PPG Foundation and corporate global social responsibility. “We’re focused on creating b
HSBC Continental Europe: 2024 Annual and Second Half Results19.2.2025 14:40:00 CET | Press release
Regulatory News: On 18 February 2025, HSBC Continental Europe’s Board of Directors reviewed the second half year results and approved the consolidated financial statements for 2024. At HSBC, our ambition is to be the preferred and most trusted international financial partner for our clients. In Continental Europe, we are focused on serving corporate and institutional clients, with a particular focus on connecting them to international markets, financing and facilitating trade within Europe and between Europe and the rest of the world. We also serve international high and ultra-high net worth clients of the HSBC Group through our private banking business in Luxembourg. In the second half of 2024, we accelerated our strategy by signing an agreement to sell our private banking business in Germany and a Memorandum of Understanding for the potential sale of our life insurance business in France1. Our results in 2024 reflected growth in wholesale transaction banking and financing, offset by
Parse Biosciences Launches 5 Million Cell Evercode WT Penta Kit for Single Cell Sequencing19.2.2025 14:15:00 CET | Press release
The most scalable and high-resolution single cell solution available Parse Biosciences, the leader in high-throughput single cell sequencing, today announced the launch of Evercode™ WT Penta and Penta 384, the first single cell RNA sequencing kits to profile 5 million cells and 384 samples in a single run. Evercode Penta and Penta 384 will begin shipping to customers the week of March 17. Scaling up single cell experiments—processing millions of cells instead of thousands—has revolutionized the way researchers study development, disease, and cellular heterogeneity. In 2021, Parse set a new benchmark for scalability of single cell experiments with the release of Evercode™ WT Mega, the industry’s highest throughput kit, enabling researchers to push the boundaries of their experimental designs. With the release of Evercode WT Penta, Parse continues to redefine the limits of single cell research. Penta is the only technology offering fixation and truly unbiased discovery of novel gene expr
Celerion Expands UK Phase 1 Clinical Research Operations With New Agreement to Relocate to Queen’s University Belfast’s iREACH Health – Clinical Research Innovation Center19.2.2025 14:00:00 CET | Press release
Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health. This state-of-the-art clinical research center, led by Queen’s University Belfast, in partnership with the Belfast Health and Social Care Trust, is set to become a cornerstone of Northern Ireland’s life sciences innovation ecosystem upon its early 2027 completion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219467591/en/ Set to complete in 2027, the state-of-the-art iREACH Health clinical research center is set to become a cornerstone of Northern Ireland's life sciences landscape. As part of this development, Celerion will relocate its U.K. Phase 1 clinical research operations to the facility, positioning it at the forefront of clinical research innovation. (Photo: Business Wire) Celerion’s Belfast clinic has a history of clinical research excellence spannin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom